Objective: This analysis was performed to assess whether antiepileptic drugs (AEDs) modulate the effectiveness of temozolomide radiochemotherapy in patients with newly diagnosed glioblastoma.
chrome P450 system and may thus enhance the metabolism of many commonly administered chemotherapy agents as well as corticosteroids. Conversely, the enzyme-inhibiting effect of valproic acid (VPA) appears clinically of lesser importance, although increased myelosuppression may develop in patients receiving nitrosoureas or cisplatinum-based chemotherapy concomitantly. 4 There is also concern that VPA increases the risk of perioperative bleeding complications, although this is not supported by the literature. 5, 6 Intrinsic antitumor activity of certain AEDs and synergy with chemotherapy or radiotherapy (RT) have been suggested in some, but not all, studies. 7 For instance, phenytoin has been attributed antimitotic and anti-invasive properties, and VPA has been suggested to induce cell differentiation, growth arrest, and apoptosis mediated by its histone deacetylase (HDAC)-inhibiting properties. 8, 9 In a recent retrospective analysis of 3 trials performed by the North Central Cancer Treatment Group, a possible association of enzymeinducing antiepileptic drug (EIAED) use with a favorable outcome in patients with glioblastoma was reported. 10 This observation prompted us to assess a potential predictive value on outcome of the AED used within the pivotal trial of concomitant and adjuvant temozolomide (TMZ) and radiotherapy (TMZ/RT3 TMZ), the current standard of care. [11] [12] [13] METHODS Patients. We retrospectively analyzed the subgroup of patients who received an AED while being treated within a pivotal large randomized clinical chemotherapy trial. In that randomized trial, 573 patients with newly diagnosed glioblastoma were treated between 2000 and 2002 with either initial RT alone or RT with concomitant and adjuvant TMZ chemotherapy (TMZ/RT3 TMZ). 11 Eligible patients had histologically confirmed glioblastoma, were aged 18 -70 years, and had a World Health Organization performance status of 0 -2. National Cancer Institute Common Toxicity Criteria were used to grade toxicity. Baseline medication was recorded in all patients, and AED use for the purpose of this analysis refers to baseline use, that is, at any time during concomitant radiochemotherapy, unless specified otherwise. The reason for the prescription of an AED was not recorded; thus, patients may have been receiving an AED because of a seizure at disease presentation or for prophylaxis during the perioperative and postoperative phase. We identified 387 patients (68% of all patients) who received any AED; 110 patients (28% of those receiving an AED) were prescribed a non-EIAED, mostly VPA, exclusively, whereas the others received at least one EIAED, either phenytoin, carbamazepine, oxcarbazepine, or phenobarbital. Patient characteristics and details of the assigned oncologic therapy and type of AED used are summarized in tables 1 and 2.
Standard protocol approvals, registrations, and patient consents. The trial was conducted by the European Organization for Research and Treatment of Cancer (EORTC) and the National Cancer Institute of Canada (NCIC) Clinical Trials Group. All patients provided written informed consent, and the study was approved by the ethics committees and competent authorities of all participating centers.
Statistical analysis.
A 2 test was used for binary and categorical factors and a Kruskal-Wallis test for continuous variables and scores to assess the significance of observed imbalances in baseline characteristics. The treatment effect on outcome (progression-free survival [PFS] or overall survival [OS]) was analyzed by univariate analysis in the 3 major subgroups (table 1) defined by the administration of an AED: no AED vs VPA only vs EIAED only. OS was defined as the time between randomization and death. Patients alive at the time of analysis were censored at the last visit. PFS was defined as the time between randomization and progression or death, which ever occurred first. Patients who did not progress were censored at the last patient visit.
Log-rank tests were used to compare PFS and OS curves. For both PFS and OS, 3 Cox proportional hazards models were fit to assess the treatment effect in each AED subgroup. Three separate Cox models with an interaction term were fit to compare treatment efficacy between AED subgroups and to estimate their predictive values for treatment efficacy on PFS and OS. All models were adjusted for possible confounding effects of 4 previously identified prognostic factors: age (score: Յ50, Ͼ50 -Յ60, and Ͼ60 years), extent of tumor resection (score: biopsy, partial resection, or complete resection), administration of corticosteroids (yes/no), and Mini-Mental State Examination (MMSE) (score: 27-30 or Ͻ27). Forest plots with Peto (unadjusted) heterogeneity tests were computed. Hazard ratios (HRs) are presented with 95% confidence intervals (CI). No adjustment for multiple comparisons was performed in this exploratory analysis. Instead, a 5% significance level was used for all analyses. A significance level of 5%-10% was considered borderline nonsignificant. The size of subgroups does not allow for sufficient power for these exploratory analyses. p values are presented to point out what the main effects are but not to provide definitive conclusions. SAS version 9.2 (SAS Institute Inc., Cary, NC) was used for all statistical analyses.
RESULTS AED use in the EORTC/NCIC trial. The pattern of AED use by patients treated in the EORTC/ NCIC trial at baseline is summarized in table 1. Table 2 shows that baseline patient characteristics were similar among patients not receiving any AED, VPA onlytreated patients, and EIAED only-treated patients. Patients treated in the TMZ/RT arm were less often treated with an AED than patients in the RT only arm (61% vs 72%, p ϭ 0.007). There was no significant imbalance in VPA only-treated patients: 30% in the TMZ/RT arm vs 26% in the RT only arm (p ϭ 0.34). There was a slight imbalance in gender distribution (p ϭ 0.06), and more patients treated with VPA in the RT only arm had a lower MMSE score (Ͻ27) compared with other subgroups (p ϭ 0.07). We also con-sidered the possibility of a bias introduced by parallel changes in patterns of care in terms of tumor treatment and AED use. To this end, we assessed the prescription of AED by year of accrual (2000, 2001, or 2002 ) and by split into cohorts (first half of patients vs second half of patients), but there was no significant change of AED prescription within this short time period (data not shown).
Information on AED use as concomitant medication was available for the duration of adjuvant TMZ administration but was not available after the end of RT for patients in the RT alone arm. Among the 287 patients in the TMZ/RT3TMZ arm, 223 started adjuvant TMZ; of these, 206 patients belonged to one of the 3 main subgroups (table 1) : 79 no AED, 88 EIAED only, and 39 VPA only. Overall, 957 cycles of TMZ were administered to the 223 patients. Of 340 adjuvant cycles given to patients without an AED at baseline (36%), 301 cycles remained without an AED (88.5%), 18 were with an EIAED (5.3%), and 5 were with VPA (1.5%). Of 375 cycles given to patients with an EIAED only at baseline (39%), 320 remained with an EIAED only (85.3%), 33 were without an AED (8.8%), and 6 were with VPA only (1.6%). Of 172 cycles given to baseline VPA only patients (18%), 128 remained with VPA (74.4%), 27 without an AED (15.7%), and 10 with an EIAED only (5.8%). When all switches, e.g., no AED to AED and vice versa, VPA to EIAED, or VPA to a combination, were counted as a change in AED status, there was no significant difference in the pattern of switch between the 3 baseline groups (p ϭ 0.2). In patients treated with an AED at baseline, the frequency of changing AED type during chemoradiotherapy was 11% with EIAED only and 18% with VPA only (p ϭ 0.4).
AED use and hematologic toxicity.
To identify differential hematologic toxicity from TMZ chemoradiotherapy, we focused on the 3 well-defined largest groups of patients: patients without any AED, patients treated with VPA only, and patients treated with an EIAED only. There was no difference in the number of adjuvant TMZ cycles across these 3 baseline AED groups ( p ϭ 0.90). There was also no difference in the rate of grade 3/4 hematologic toxicity during concomitant TMZ among these groups (data not shown). However, patients starting adjuvant TMZ while taking VPA had thrombocytopenia ( p ϭ 0.002), neutropenia ( p ϭ 0.004), and leukopenia ( p ϭ 0.03) more often than patients without an AED or patients with an EIAED, whereas no significant difference was found for anemia (table e-1 on the Neurology ® Web site at www.neurology.org). These differences persisted when the patients who switched AED treatment were removed from the analysis (data not shown). Moreover, VPA onlytreated patients had 30% of the adjuvant cycles delayed compared with 16% in EIAED only-treated patients and 17% in no AED patients ( p ϭ 0.0001). Further, the overall benefit from the addition of TMZ was similar in patients without an AED (PFS: p Ͻ 0.0001, HR 0.50, 95% CI 0.36 -0.69; OS: p ϭ 0.016, HR 0.67, 95% CI 0.49 -0.93 and with an AED Further analyses were again restricted to the 3 major groups of patients as detailed in table 1: patients without any AED, patients treated with VPA only, and patients treated with an EIAED only. Table 3 shows that patients treated with VPA alone (97 [16.9%]) had a superior survival benefit from TMZ/RT (HR 0.39, 95% CI 0.24 -0.63) compared with patients treated with an EIAED only (252 [44%]) (HR 0.69, 95% CI 0.53-0.90) or patients without any AED (HR 0.67, 95% CI 0.49 -0.93). Interaction tests were significant for the VPA only vs EIAED only comparison ( p ϭ 0.042), borderline nonsignificant for VPA only vs no AED ( p ϭ 0.09), and not significant for EIAED only vs no AED ( p ϭ 0.76). Corresponding OS data are provided in table 4 and figure 1A . No such effect was seen for PFS (table e-2, figure e-1). This discrepancy between PFS and OS could not be attributed to different salvage treatments administered at recurrence across the 3 groups of patients (data not shown). Similar analyses were also separately conducted for the 2 most commonly used EIAEDs, phenytoin and carbamazepine, but neither drug had a statistically significant impact either (data not shown).
Methylation of the O 6 -methylguanine methyltransferase (MGMT) gene has been identified as a predictor of benefit from TMZ in this trial. 12 Thus, we explored the possibility that an uneven distribution of patients with methylated vs unmethylated tumors accounted for the association of VPA use and outcome. However, this was not the case: the rates of MGMT promoter methylation in the 3 groups by treatment arm were 10 of 20 (50.0%) for no AED, 10 of 23 (43%) for VPA only, and 22 of 48 (46%) for EIAED only in the RT arm and 18 of 41 (44%) DISCUSSION This retrospective analysis of the dataset from the pivotal trial for TMZ in newly diagnosed glioblastoma 11-13 suggests a predictive impact on survival of AED choice in patients with glioblastoma treated according to current standards of care.
Patients who were treated with TMZ/RT3 TMZ and received VPA appeared to have a better outcome than patients treated with an EIAED and even patients not receiving any AED. This effect could not be attributed to a differential distribution of patients with tumors with vs without MGMT promoter methylation within the subgroups analyzed. At least 2 mechanisms underlying this interesting observation may be considered. TMZ is a prodrug converted to 3-methyl-(triazen-1-yl)imidazole-4carboxamide, which is either hydrolyzed or unchanged before excretion. No effect of phenytoin, carbamazepine, or barbituric acid on TMZ clearance has been observed, whereas VPA decreased its clearance by 5% (www.temodar.com). To some extent, the increased hematologic toxicity during adjuvant TMZ with VPA (table e-1) may thus be related to increased bioavailability of TMZ. However, thrombocytopenia is not an uncommon side effect in patients treated with VPA alone.
Alternatively, our observation may lend support to the notion that the HDAC inhibitory properties of VPA mediate the superior benefit derived from radiochemotherapy. Improved survival for patients with a number of tumors has been reported if HDAC-inhibitory agents including VPA are combined with one or more chemotherapeutic agents. 8, 14, 15 Previously, a prolonged survival of 14 months vs 11 months was observed in patients with glioblastoma treated with adjuvant CCNU who received antiepileptic therapy with a non-EIAED, mainly VPA, compared with patients who received an EIAED, mainly carbamazepine. 16 Exploratory trials using HDAC inhibitors more potent than VPA such as vorinostat in combination with TMZ radiochemotherapy are ongoing and may provide further support for this hypothesis. Selective HDAC inhibitors might also have a preferred tolerability profile compared with VPA, which induces weight gain, alopecia, and tremor in some patients.
Our results must be interpreted with caution. They were generated from an unplanned and insufficiently powered retrospective analysis. The indication for and the choice of an AED were decided according to local practice before enrollment into the clinical trial. Although we have no evidence for a bias-the decisions for prescription and type of AED were at the investigators' discretion, and randomization was stratified by participating center-the observed differences may be the result of patient selection. This potential flaw might be tempered by the balancing effect of the treatment randomization and adjustment for known prognostic factors in all analyses. However, there was an imbalance in that more patients with a lower MMSE score (Ͻ27) were treated with VPA than with an EIAED in the RT arm (table 2) , enhancing the TMZ treatment effect observed. The indication for the prescription of an AED and the duration of use were not recorded in detail, and we suspect that several patients may have received primary antiseizure prophylaxis in the perioperative and postoperative period, which was common practice in many centers in 2000 -2002. Today, more and more neurooncology centers restrict the indication for an AED to secondary prophylaxis and prefer newer AEDs such as levetiracetam over either an EIAED or VPA.
No significant difference in outcome was observed for PFS in any of the analyses, but this secondary study endpoint is subject to many additional limitations, including the occurrence of pseudoprogression and is also subject to variations in medical practice, such as frequency of imaging, which may be summarized as information bias. Moreover, the date of progression was not centrally reviewed in this trial. Importantly, if VPA truly has radiochemosensitizing effects, it may also enhance the incidence of pseudoprogression, possibly diluting a PFS effect in a trial lacking a central radiology review for PFS determination.
Our study and this analysis are unique and have some distinguishing strengths compared with other reports. 10, 17, 18 Our analysis is contemporary and evaluates patients treated with the current standard of care with concomitant chemoradiotherapy, 11, 13 whereas a previous report evaluated a pooled database of clinical trials with negative results. 10 In addition, by analyzing the HR for treatment benefit within a randomized trial rather than analyzing prognostic values, we counterbalance potential inhomogeneities of hidden prognostic factors.
Our data suggest that combined modality therapy may be more effective in patients with newly diagnosed glioblastoma treated with VPA than in patients treated with an EIAED. A more intriguing finding is that VPA-treated patients may even have a better outcome than patients receiving no AED at all. One explanation for the observed interaction between VPA and TMZ/RT is the inhibition of HDAC by VPA, 19, 20 and autophagy of glioma cells may possibly also be induced by VPA. 21 The presence of better acetylation status of histones may allow greater efficacy of chemotherapy and may explain the longer survival in patients receiving VPA in combination with another chemotherapeutic agent, i.e., TMZ, and not with the use of EIAED or without any AED. 8, 9 The full potential of VPA may not have been exploited because VPA was not given during the full course of TMZ chemoradiotherapy in some of the patients included in the VPA group.
Despite the limitations of this retrospective analysis, these results suggest that the choice of AED in patients with brain tumors should be carefully considered because it may affect survival. The present observation also further supports a recent trend to favor an non-EIAED for patients with a malignancy to allow administration of modern chemotherapy and targeted agents that often show increased hepatic metabolism if patients are given an EIAED.
